ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Doctors can now analyse their historical prescriptions within a few clicks enabling them to identify different cohorts of patients and the treatment given to them
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
The company will manufacture a cancer immunotherapy product from 2022
Scoliosis is a disorder of the spine, and its surgeries are generally done only in large hospitals in big cities.
It is a novel oral NLRP3 inflammasome inhibitor
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Subscribe To Our Newsletter & Stay Updated
